News On Projects
Products & Services
Projects Database
Tenders Database
E - Newsletter
EPXonline.com
Project Financing
Contracts & Awards
Energy
Electricity
Mining
Oil & Gas
Infrastructure
Airport
Port
Railway
Road
Freezone
Construction
Manufacturing
Cement
Engineering
Automobile
Plastic
Metal
Textile
Paper & Packaging
Leather
Sugar
Edible Oil
Electrical & Electro
Processing
Chemical
Drugs & Pharma
Fertiliser
I-C-T
Communication
IT
Telecom
Water
Pump Station
Water Treatment
Water Supply
Hospitality
Hotel
Restaurant
Resort
Entertainment
Sports
Multiplex
Theme Park
Food & Beverages
Hospital
Service
Social
Science
Irrigation
Government
Policy
Economic Indicators
Company News
Commerce
Miscellaneous
News Uploaded On : Wednesday, April 13, 2016 10:15:00 AM IND Back  |  Latest Projects  |  Latest Tenders
 
 E-mail this to a friend        Printable version       Story Viewed 2676 Times
Rusan Pharma aims to double turnover to Rs 600 cr by 2018
With a focus on research and development (R&D), Rusan Pharma, which specialises in pain management, opioid de-addiction & anti-infectives therapies, is aiming to double its turnover to Rs 600 by 2018.

To augment its research capability, the company will invest Rs 100 crore in a R&D centre and a manufacturing unit in Kandla (Gujarat). With this fresh investment, it will focus on research and manufacture of de-addiction and pain management drugs for domestic market and export. As a part of its expansion plan, Rusan Pharma is also planning to set up a clinical research organisation.

Rusan Pharma plans to manufacture transdermal patches at Kandla. The company, which currently exports products to Europe, Russia, South Africa and South East Asia, aims to expand exports to the US and Canada.

BS

Post your comments:

Your name: *
E-Mail Id:
E-mail ID will not be published
Comment: *
Maximum 500 Characters
    
Related Stories
China’s Fosun bids to buy India’s Gland Pharma.
Alembic Pharma forms JV with Orbicular for derma products.
Indoco Remedies shares soar 19% on USFDA nod for Goa plant.
GSK Pharma plans Rs. 500-cr expansion of its Nashik unit.
Mankind Pharma to invest Rs. 150 crore in Paonta Sahib plant.
Green panel okays Aurobindo Pharma's Telangana unit expansion.
GSK begins work on new factory to make tablets and capsules.
IICT promises to assist pharma industry in AP.
IDPL modernises tablet making unit at Gurgaon plant.
Aurobindo Pharma to build three formulation plants in Andhra Pradesh, Telangana.
RELATED PROJECTS & TENDERS
ADVERTISEMENT
MOST POPULAR STORIES NOW
For all enquiries please contact
Tel: 022 - 25961254, 25960909
Mobile: 9821464666/09751178830
Mail: marketing@newsonprojects.com

OUR OTHER PRODUCTS & SERVICES:    Projects Database   |   Project e-Newsletter   |   Tenders Database   |   Commissioned Power Plants   |   Company Index
About Us   |   Contact Us   |   Terms of Use   |   Advertise with Us   |   Privacy Policy   |   Disclaimer   |   Feedback